ANTIBODY TO CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) 05031656160

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05,06 report with the FDA on 2013-10-09 for ANTIBODY TO CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) 05031656160 manufactured by Roche Diagnostics.

Event Text Entries

[3800358] The customer first reported that since (b)(6) 2013, they had been having ongoing issues with quality control recovery on antibody to cyclic citrullinated peptide (anti-ppc). The customer started using new reagent lot 17233201 on (b)(6) 2013 on an elecsys 2010 disk analyzer. The customer ran a patient comparison on this new lot consisting of 5 patient samples. Of the five samples, one had an erroneous result that was reported outside of the laboratory. The sample initially resulted as 300. 4 u/ml. The customer was asked, but did not know when the sample was initially tested. This initial result was believed to be the correct value. The sample was repeated on (b)(6) 2013 as part of the comparison study and resulted as 189. 5 u/ml. The 189. 5 u/ml value was reported outside of the laboratory. The patient was not adversely affected. The elecsys 2010 disk analyzer serial number was (b)(4). The customer was sent a different reagent lot and repeated 20 samples that were run over the past month. The initial results for these samples were questioned but were not found to be erroneous. The medical director for the site stated that the differences were not clinically significant, so no patient reports were amended. The field service representative determined that the reagent was defective. The customer was provided a new reagent lot (173360). The field service representative cleaned the measuring cell manually, performed a high voltage adjustment, deleted previous calibrations, and performed a blank cell calibration. The customer ran calibration and quality controls. Reagent pack lot 17233201 passed calibration, but controls failed the customer's 2sd criteria. Reagent pack lot 173660 passed calibration and controls were on the mean.
Patient Sequence No: 1, Text Type: D, B5


[11124198] It was unknown if the initial reporter sent report to the fda.
Patient Sequence No: 1, Text Type: N, H10


[11244097] The customer did not know which reagent lot was used to initially test the sample.
Patient Sequence No: 1, Text Type: N, H10


[20900979] A specific root cause could not be identified.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1823260-2013-06200
MDR Report Key3395912
Report Source05,06
Date Received2013-10-09
Date of Report2013-11-14
Date of Event2013-09-12
Date Mfgr Received2013-09-19
Date Added to Maude2013-10-09
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location3
Manufacturer ContactNA JENNIFER WOLFGRAM
Manufacturer Street9115 HAGUE ROAD NA
Manufacturer CityINDIANAPOLIS IN 46250
Manufacturer CountryUS
Manufacturer Postal46250
Manufacturer Phone3175217008
Manufacturer G1ROCHE DIAGNOSTICS GMBH
Manufacturer StreetSANDHOFERSTRASSE 116 NA
Manufacturer CityMANNHEIM (BADEN-WURTTEMBERG) 68305
Manufacturer CountryGM
Manufacturer Postal Code68305
Single Use3
Previous Use Code3
Removal Correction NumberNA
Event Type3
Type of Report3

Device Details

Brand NameANTIBODY TO CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP)
Generic NameANTIBODIES, ANTI-CYCLIC CITRULLINATED PEPTIDE (CCP)
Product CodeNHX
Date Received2013-10-09
Model NumberNA
Catalog Number05031656160
Lot Number17233201
ID NumberNA
Device Expiration Date2013-10-31
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerROCHE DIAGNOSTICS
Manufacturer Address9115 HAGUE ROAD NA INDIANAPOLIS IN 46250 US 46250


Patients

Patient NumberTreatmentOutcomeDate
10 2013-10-09

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.